AccessDx PGx Profile Pharmacogenomics Test

AccessDx Laboratory has launched an expanded pharmacogenomics test, AccessDx PGx Profile, to identify potential risks for adverse drug reactions or reduced medication efficacy. The test assesses a targeted range of individual genes and genetic variants, enabling providers to evaluate risks associated with an extensive list of medications known to be influenced by the genetic variants. The panel provides insights related to specific ethnic indicators, clinical areas, and medical conditions, the firm said.